- Home
- Publications
- Publication Search
- Publication Details
Title
Endocrine toxicities of immune checkpoint inhibitors
Authors
Keywords
-
Journal
Nature Reviews Endocrinology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-04-19
DOI
10.1038/s41574-021-00484-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study
- (2020) Norio Okada et al. BRITISH JOURNAL OF CANCER
- Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune‐checkpoint inhibitors
- (2020) Chiaki Kurimoto et al. CANCER SCIENCE
- Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes
- (2020) Z. Quandt et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Reporting of Immune Checkpoint Inhibitor Therapy–Associated Diabetes, 2015–2019
- (2020) Jiaqing Liu et al. DIABETES CARE
- Immune Checkpoint Inhibitor‐Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis
- (2020) Virginie Grouthier et al. ONCOLOGIST
- Demographic factors associated with toxicity in patients treated with anti-programmed cell death-1 therapy
- (2020) Kaustav P Shah et al. Cancer Immunology Research
- Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand
- (2020) James Randall Patrinely et al. EUROPEAN JOURNAL OF CANCER
- Central diabetes insipidus related to anti-programmed cell-death 1 protein active immunotherapy
- (2020) Maria V. Deligiorgi et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research
- (2020) Douglas B Johnson et al. LANCET ONCOLOGY
- Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial
- (2020) Alexander M. M. Eggermont et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
- (2020) Paolo A Ascierto et al. LANCET ONCOLOGY
- 15. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes—2021
- (2020) DIABETES CARE
- Nivolumab Induced Thyroid Dysfunction: Unusual Clinical Presentation and Challenging Diagnosis
- (2019) Carmine Iadarola et al. Frontiers in Endocrinology
- Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma
- (2019) Beckey Trinh et al. Journal for ImmunoTherapy of Cancer
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
- (2019) John A. Thompson et al. Journal of the National Comprehensive Cancer Network
- Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial
- (2019) Celeste Lebbé et al. JOURNAL OF CLINICAL ONCOLOGY
- A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors
- (2019) Jeroen de Filette et al. HORMONE AND METABOLIC RESEARCH
- T-Lymphocyte Infiltration to Islets in the Pancreas of a Patient Who Developed Type 1 Diabetes After Administration of Immune Checkpoint Inhibitors
- (2019) Sho Yoneda et al. DIABETES CARE
- Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
- (2019) Filipe Martins et al. Nature Reviews Clinical Oncology
- Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline
- (2019) G E Bekkering et al. BMJ-British Medical Journal
- The impact of high-dose glucocorticoids on the outcome of immune checkpoint inhibitor-related thyroid disorders
- (2019) Chanjuan Ma et al. Cancer Immunology Research
- Association of Checkpoint Inhibitor–Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non–Small Cell Lung Cancer
- (2019) Fiamma Berner et al. JAMA Oncology
- Successful Treatment of Immune Checkpoint Inhibitor–Induced Diabetes Mellitus With Infliximab
- (2019) Beckey Trinh et al. DIABETES CARE
- Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review
- (2019) Jeroen M.k. de Filette et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Checkpoint inhibitor associated autoimmune diabetes (CIADM) is distinct from type 1 diabetes
- (2019) Venessa H M Tsang et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis
- (2019) Douglas B. Johnson et al. NATURE MEDICINE
- Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer
- (2019) Junji Koyama et al. Journal of Thoracic Disease
- Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation
- (2019) Tawnie J Braaten et al. ANNALS OF THE RHEUMATIC DISEASES
- Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis
- (2019) Alexander Faje et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
- (2019) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- The long-term outcome of treatment for Graves' hyperthyroidism
- (2019) Gabriel Sjölin et al. THYROID
- Factors Associated With Immune Checkpoint Inhibitor–Related Myocarditis
- (2019) Yoshito Zamami et al. JAMA Oncology
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- (2019) Barbara Burtness et al. LANCET
- Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Peter Schmid et al. LANCET ONCOLOGY
- Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities
- (2019) Salahaldin A. Tahir et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609
- (2019) Ahmad A. Tarhini et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients
- (2019) Anupam Kotwal et al. THYROID
- Immune check point inhibitors-induced hypophysitis: a retrospective analysis of the French Pharmacovigilance database
- (2019) Julie Garon-Czmil et al. Scientific Reports
- High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma
- (2018) Alexander T. Faje et al. CANCER
- Quality of life in patients with adrenal disease: A systematic review
- (2018) Winnie Ho et al. CLINICAL ENDOCRINOLOGY
- Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors
- (2018) Angeliki M. Stamatouli et al. DIABETES
- Early B cell changes predict autoimmunity following combination immune checkpoint blockade
- (2018) Rituparna Das et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety of Programmed Death–1 Pathway Inhibitors Among Patients With Non–Small-Cell Lung Cancer and Preexisting Autoimmune Disorders
- (2018) Giulia C. Leonardi et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- (2018) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Interferon-gamma drives programmed death-ligand 1 expression on islet β cells to limit T cell function during autoimmune diabetes
- (2018) Kevin C. Osum et al. Scientific Reports
- ImmuneCheckpoint Inhibitor-Induced Hypoparathyroidism Associated with Calcium-Sensing Receptor-Activating Autoantibodies
- (2018) Paramarajan Piranavan et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
- (2018) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
- (2018) Leora Horn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune-Related Thyroiditis with Immune Checkpoint Inhibitors
- (2018) Priyanka C. Iyer et al. THYROID
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- (2018) Daniel Y. Wang et al. JAMA Oncology
- Increased Reporting of Immune Checkpoint Inhibitor–Associated Diabetes
- (2018) Jordan J. Wright et al. DIABETES CARE
- Immune Checkpoint Inhibitor Toxicity in 2018
- (2018) Douglas B. Johnson et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer
- (2018) Yukihiro Toi et al. JAMA Oncology
- Anti–PD-L1 Treatment Induced Central Diabetes Insipidus
- (2017) Chen Zhao et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms
- (2017) Danae A Delivanis et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy
- (2017) Jarushka Naidoo et al. JOURNAL OF CLINICAL ONCOLOGY
- Transient pituitary ACTH-dependent Cushing syndrome caused by an immune checkpoint inhibitor combination
- (2017) Jeremy Lupu et al. MELANOMA RESEARCH
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma
- (2017) Allison S. Betof et al. ONCOLOGIST
- Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy
- (2017) Hyunju Lee et al. Cancer Immunology Research
- Human beta cell mass and function in diabetes: Recent advances in knowledge and technologies to understand disease pathogenesis
- (2017) Chunguang Chen et al. Molecular Metabolism
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
- (2017) I. Puzanov et al. Journal for ImmunoTherapy of Cancer
- Ipilimumab-Induced Hypophysitis and Uveitis in a Patient With Metastatic Melanoma and a History of Ipilimumab-Induced Skin Rash
- (2017) Neelima N. Nallapaneni et al. Journal of the National Comprehensive Cancer Network
- Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
- (2016) A. M. Menzies et al. ANNALS OF ONCOLOGY
- A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome
- (2016) Elizabeth Hansen et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline
- (2016) Stefan R. Bornstein et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Combinatorial approach to cancer immunotherapy: strength in numbers
- (2016) Anna E. Vilgelm et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade
- (2016) Douglas B. Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systemic glucocorticoid therapy and adrenal insufficiency in adults: A systematic review
- (2016) Rebecca M. Joseph et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis
- (2016) Douglas S. Ross et al. THYROID
- Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
- (2016) Krista Dubin et al. Nature Communications
- Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
- (2016) Douglas B. Johnson et al. JAMA Oncology
- Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction
- (2016) Bridgette A. Kanz et al. Journal for ImmunoTherapy of Cancer
- Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy
- (2016) Jared R. Lowe et al. Journal for ImmunoTherapy of Cancer
- Disease-Specific as Well as Generic Quality of Life Is Widely Impacted in Autoimmune Hypothyroidism and Improves during the First Six Months of Levothyroxine Therapy
- (2016) Kristian Hillert Winther et al. PLoS One
- Adrenal Insufficiency in Corticosteroids Use: Systematic Review and Meta-Analysis
- (2015) Leonie H. A. Broersen et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center
- (2015) Douglas B. Johnson et al. Cancer Immunology Research
- Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study
- (2014) L. Min et al. CLINICAL CANCER RESEARCH
- Ipilimumab-Induced Hypophysitis: A Detailed Longitudinal Analysis in a Large Cohort of Patients With Metastatic Melanoma
- (2014) Alexander T. Faje et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
- (2014) S. Iwama et al. Science Translational Medicine
- PD-1, but Not PD-L1, Expressed by Islet-Reactive CD4 + T Cells Suppresses Infiltration of the Pancreas During Type 1 Diabetes
- (2013) Kristen E. Pauken et al. DIABETES
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Practice Guidelines for Hypothyroidism in Adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association
- (2012) Jeffrey R. Garber et al. THYROID
- Drug-Induced Graves Disease From CTLA-4 Receptor Suppression
- (2011) Gary Borodic et al. OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY
- Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy
- (2010) Le Min et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Thyrotropin and Thyroid Antibodies as Predictors of Hypothyroidism: A 13-Year, Longitudinal Study of a Community-Based Cohort Using Current Immunoassay Techniques
- (2010) John P. Walsh et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More